Back to top
more

IDEXX Laboratories (IDXX)

(Real Time Quote from BATS)

$484.93 USD

484.93
27,508

+12.58 (2.66%)

Updated Sep 9, 2024 10:18 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 249)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

IDEXX (IDXX) Earnings Beat Estimates in Q4, Margins Rise

by Zacks Equity Research

IDEXX (IDXX) registeres strong contribution from its CAG business in the fourth quarter despite pandemic-induced challenges.

Why You Should Add AngioDynamics (ANGO) to Your Portfolio

by Zacks Equity Research

Investor confidence is high in AngioDynamics (ANGO) stock, courtesy of its solid prospects.

Idexx Laboratories (IDXX) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Idexx (IDXX) delivered earnings and revenue surprises of 40.56% and 5.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Thermo Fisher (TMO) Q4 Earnings Beat on Growth in All Segments

by Zacks Equity Research

Thermo Fisher (TMO) records $3.2 billion of COVID-19 response revenues and accelerated growth in base business in Q4.

Urmimala Biswas headshot

MedTech Stock Earnings on Feb 2: IDXX, MCK & More

by Urmimala Biswas

In Q4, MedTech stocks are expected to have gained from month-wise sales rebound in many states and regions. However, international sales might have been dampened.

NextGen Healthcare (NXGN) Loses 8.8% Despite Q3 Earnings Beat

by Zacks Equity Research

NextGen Healthcare's (NXGN) fiscal third-quarter earnings reflect strong segmental performance.

Accuray (ARAY) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Accuray (ARAY) registers growth in Service revenues during fiscal Q2.

ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q3

by Zacks Equity Research

ABIOMED's (ABMD) international Impella revenues improve in Q3.

Stryker (SYK) Q4 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Stryker's (SYK) fourth-quarter earnings reflect strong segmental performance.

CONMED (CNMD) Q4 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Despite weak segmental performance in fourth quarter, CONMED (CNMD) showed strength and resilience in amid a tough operating environment.

Hologic (HOLX) Q1 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Hologic (HOLX) exhibited robust segmental growth in first-quarter fiscal 2021, driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.

Edwards Lifesciences (EW) Q4 Earnings Fall Shy of Estimates

by Zacks Equity Research

Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed robust performances in TMTT business in Q4.

Varian (VAR) Q1 Earnings Beat Estimates, Revenues Miss Mark

by Zacks Equity Research

Varian's (VAR) receipt of 13 Ethos orders in fiscal Q1 raises investors' optimism on the stock.

What's in Store for IDEXX Laboratories (IDXX) in Q4 Earnings?

by Zacks Equity Research

IDEXX's (IDXX) fourth-quarter top line is likely to have benefited from strength in CAG and LPD businesses.

Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Hologic's (HOLX) CE-Marked Fluent System Launched in Europe

by Zacks Equity Research

Hologic (HOLX) aims to optimize, simplify and streamline hysteroscopic workflow with the latest European launch of its fluid management system.

Here's Why You Should Retain AmerisourceBergen (ABC) Now

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches.

Intuitive Surgical (ISRG) Q4 Earnings Beat Estimates, Up Y/Y

by Zacks Equity Research

Intuitive Surgical's (ISRG) fourth-quarter results reflect improvement in procedure volume.

Here's Why You Should Retain AMN Healthcare (AMN) Stock Now

by Zacks Equity Research

AMN Healthcare (AMN) continues to gain traction from its wide range of services, and Healthcare MSP. Intense competition remains a woe.

Why You Should Retain Pacific Biosciences (PACB) Stock Now

by Zacks Equity Research

Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of solid prospects.

    Sreoshi Bera headshot

    ESG Stocks to Gather Speed Under Biden's Leadership: 5 Picks

    by Sreoshi Bera

    Biden's administration plans to address climate change and take ESG initiatives. This call for investing in Shopify (SHOP), Magna International (MGA), IDEXX Lab (IDXX), Facebook (FB) and PayPal (PYPL).

    Here's Why You Should Add Hologic (HOLX) to Your Portfolio

    by Zacks Equity Research

    Investors continue to be optimistic about Hologic (HOLX) due to a slew of regulatory approvals and buyouts.

    Omnicell (OMCL) Reports Encouraging 2020 Preliminary Results

    by Zacks Equity Research

    Per the preliminary announcement, Omnicell (OMCL) projects 2020 total revenues to surpass its previous guidance.

    Cardiovascular Systems' (CSII) OAS Gets CE Mark for Use in Europe

    by Zacks Equity Research

    Cardiovascular Systems (CSII) aims to expand treatment options in Europe for patients suffering from severely calcified coronary artery disease following the receipt of regulatory clearance.

    Haemonetics (HAE) Hits New 52-Week High: What's Driving It?

    by Zacks Equity Research

    Haemonetics (HAE) is optimistic about maintaining a robust product portfolio amid the pandemic-led business disruptions.